Aoki J, Ishiyama K, Taniguchi S, Fukuda T, Ohashi K, Ogawa H, Kanamori H, Eto T, Iwato K, Sakamaki H, Morishima Y, Nagamura T, Atsuta Y, Takami A: Outcome of allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia patients with central nervous system involvement. Biol Blood Marrow Transplant, 20(12): 2029-2033, 2014.
Aoki T, Izutsu K, Suzuki R, Nakaseko C, Arima H, Shimada K, Tomita A, Sasaki M, Takizawa J, Mitani K, Igarashi T, Maeda Y, Fukuhara N, Ishida F, Niitsu N, Ohmachi K, Takasaki H, Nakamura N, Kinoshita T, Nakamura S, Ogura M: Prognostic significance of pleural or pericardial effusion and the implication of optimal treatment in primary mediastinal large B-cell lymphoma: a multicenter retrospective study in Japan. Haematologica, 99(12): 1817-1825, 2014.
Aoki J, Kimura K, Kakihana K, Ohashi K, Sakamaki H: Efficacy and tolerability of Entecavir for hepatitis B virus infection after hematopoietic stem cell transplantation. Springerplus, 3: 450, 2014.
Aoki J, Ohashi K, Mitsuhashi M, Murakami T, Oakes M, Kobayashi T, Doki N, Kakihana K, Sakamaki H: Posttransplantation bone marrow assessment by quantifying hematopoietic cell-derived mRNAs in plasma exosomes/microvesicles. Clin Chem, 60(4):675-682, 2014.
Aoki J, Tsubokura M, Kakihana K, Oshikawa G, Kobayashi T, Doki N, Sakamaki H, Ohashi K: The predictive value for pulmonary infection by area over the neutrophil curve (D-index) in patients who underwent reduced intensity hematopoietic stem cell transplantation. Pathol Oncol Res, 20(4): 879-883, 2014.
Chihara D, Izutsu K, Kondo E, Sakai R, Mizuta S, Yokoyama K, Kaneko H, Kato K, Hasegawa Y, Chou T, Sugahara H, Henzan H, Sakamaki H, Suzuki R, Suzumiya J: High-Dose Chemotherapy with Autologous Stem Cell Transplantation for Elderly Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma: A Nationwide Retrospective Study. Biol Blood Marrow Transplant, 20(5): 684-689, 2014.
Fujisawa S, Nakamae H, Ogura M, Ishizawa KI, Taniwaki M, Utsunomiya A, Matsue K, Takamatsu Y, Usuki K, Tanimoto M, Ishida Y, Akiyama H, Onishi S: Efficacy and safety of dasatinib versus imatinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP): Subset analysis of the DASISION trial with 2-year follow-up. Int J Hematol, 99(2): 141-153, 2014.
Hayakawa F, Sakura T, Yujiri T, Kondo E, Fujimaki K, Sasaki O, Miyatake J, Handa H, Ueda Y, Aoyama Y, Takada S, Tanaka Y, Usui N, Miyawaki S, Suenobu S, Horibe K, Kiyoi H, Ohnishi K, Miyazaki Y, Ohtake S, Kobayashi Y, Matsuo K, Naoe T; Japan Adult Leukemia Study Group (JALSG): Markedly improved outcomes and acceptable toxicity in adolescents and young adults with acute lymphoblastic leukemia following treatment with a pediatric protocol: a phase II study by the Japan Adult Leukemia Study Group. Blood Cancer Journal, 4: e252, 2014.
Inokuchi K, Kumagai T, Matsuki E, Ohashi K, Shinagawa A, Hatta Y, Takeuchi J, Yoshida C, Wakita H, Kozai Y, Shirasugi Y, Fujisawa S, Iwase O, Yano S, Okamoto S, Oba K, Sakamoto J, Sakamaki H: Efficacy of Molecular Response at 1 or 3 Months after the Initiation of Dasatinib Treatment Can Predict an Improved Response to Dasatinib in Imatinib-Resistant or Imatinib-Intolerant Japanese Patients with Chronic Myelogenous Leukemia during the Chronic Phase. J Clin Exp Hematop, 54(3): 197-204, 2014.
Ishii Y, Tomita N, Tateishi U, Ishiyama Y, Yamamoto E, Hattori Y, Hagihara M, Yamazaki E, Ishigatsubo Y: The rate of reduction in the maximum standardized uptake value from the initial to the post-R-CHOP therapy in positron emission tomography scan predicts disease progression in diffuse large B cell lymphoma patients. Med Oncol, 31(3): 880, 2014.
Kanda J, Fuji S, Kato S, Takami A, Tanaka J, Miyamura K, Ohashi K, Fukuda T, Ozawa Y, Kanamori H, Eto T, Kobayashi N, Iwato K, Morishima Y, Sakamaki H, Atsuta Y, Kanda Y on behalf of the HLA Working Group, the Donor/Source Working Group, the Adult AML Working Group, and the Adult ALL Working Group of the Japan Society for Hematopoietic Cell Transplantation: Decision analysis for donor selection in stem cell transplantation - HLA-8/8 allele-matched unrelated donor vs. HLA-1 AG mismatched related donor. Blood Cancer J, 4:e263-271, 2014.
Kihara R, Nagata Y, Kiyoi H, Kato T, Yamamoto E, Suzuki K, Chen F, Asou N, Ohtake S, Miyawaki S, Miyazaki Y, Sakura T, Ozawa Y, Usui N, Kanamori H, Kiguchi T, Imai K, Uike N, Kimura F, Kitamura K, Nakaseko C, Onizuka M, Takeshita A, Ishida F, Suzushima H, Kato Y, Miwa H, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Ogawa S, Naoe T: Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients. Leukemia, 28(8): 1586-1595, 2014.
Konuma T, Ooi J, Uchida N, Ogawa H, Ohashi K, Kanamori H, Aotsuka N, Onishi Y, Yamaguchi H, Kozai Y, Nagamura-Inoue T, Kato K, Suzuki R, Atsuta Y, Kato S, Asano S, Takahashi S: Granulocyte colony-stimulating factor combined regimen in cord blood transplantation for acute myeloid leukemia: a nationwide retrospective analysis in Japan. Haematologica, 99(12): e264-268, 2014.
Kumagai T, Matsuki E, Inokuchi K, Ohashi K, Shinagawa A, Takeuchi J, Yoshida C, Okamoto S, Wakita H, Kozai Y, Shirasugi Y, Fujisawa S, Iwase O, Yano S, Nishiwaki K, Oba K, Sakamoto J, Sakamaki H: Relative increase in lymphocytes from as early as 1 month predicts improved response to dasatinib in chronic-phase chronic myelogenous leukemia. Int J Hematol, 99(1): 41-52, 2014.
Matsumoto K, Yamamoto W, Ogusa E, Ishigatsubo Y, Kanamori H: Prognostic index for relapsed acute leukemia after allogeneic stem cell transplant. Leuk Lymphoma, 55(12): 2808-2812, 2014.
Matsumoto K, Yamamoto W, Ogusa E, Sugimoto E, Maruta A, Ishigatsubo Y, Kanamori H: Impact of pretransplant serum ferritin on the outcome in adult patients receiving cord blood transplantation for acute leukemia. Leuk Lymphoma, 55(2): 460-461, 2014.
Matsumoto K, Yamamoto W, Ogusa E, Tanaka M, Maruta A, Ishigatsubo Y, Kanamori H: Disseminated Cunninghamella bertholletiae infection with septic pulmonary embolism after allogeneic bone marrow transplantation. Transpl Infect Dis, 16(2): 304-306, 2014.
Miyazaki T, Kim YS, Yoon JH, Wang H, Suzuki T, Morse CH 3rd: The 3’-5’ DNA exonuclease TREX1 directly interacts with poly (ADP-ribose) polymerase-1 (PARP1) during the DNA damage response. The Journal of Biological Chemistry, 289(47): 32548-32558, 2014.
Mizuta S, Matsuo K, Imai K, Nishiwaki S, Kanamori H, Ohashi K, Fukuda T, Onishi Y, Miyamura K, Takahashi S, Onizuka M, Suzuki R, Atsuta Y, Morishima Y, Kato K, Sakamaki H, Tanaka J: Pre-transplant administration of imatinib for allogeneic hematopoietic stem cell transplantation in patients with BCR-ABL-positive acute lymphoblastic leukemia. Blood, 123(15): 2325-2332, 2014.
Nakajima Y, Tomita N, Watanabe R, Ishiyama Y, Yamamoto E, Ishibashi D, Itabashi M, Koyama S, Takahashi H, Numata A, Takasaki H, Kawasaki R, Kuwabara H, Tanaka M, Hashimoto C, Fujimaki K, Sakai R, Motomura S, Ishigatsubo Y: Prognostic significance of serum beta-2 microglobulin level in Hodgkin lymphoma treated with ABVD-based therapy. Med Oncol, 31(9): 185, 2014.
Nakaya A, Mori T, Tanaka M, Tomita N, Nakaseko C, Yano S, Fujisawa S, Sakamaki H, Aotsuka N, Yokota A, Kanda Y, Sakura T, Nanya Y, Saitoh T, Kanamori H, Takahashi S, Okamoto S: Does the hematopoietic cell transplantation specific comorbidity index (HCT-CI) predict transplant outcomes? : A prospective multicenter validation study of the Kanto Study Group for Cell Therapy (KSGCT). Biol Blood Marrow Transplant, 20(10): 1553-1559, 2014.
Numata A, Tanaka M, Matsumoto K, Takasaki H, Tachibana T, Fujimaki K, Sakai R, Fujisawa S, Tomita N, Fujita H, Maruta A, Ishigatsubo Y, Kanamori H: Validation of the European Group for Blood and Marrow Transplantation (EBMT) risk score in patients receiving allogeneic hematopoietic stem cell transplantation at a single center in Japan. Clin Transplant, 28(4):403-409, 2014.
Shinagawa K, Yanada M, Sakura T, Ueda Y, Sawa M, Miyatake J, Dobashi N, Kojima M, Hatta Y, Emi N, Tamaki S, Gomyo H, Yamazaki E, Fujimaki K, Asou N, Matsuo K, Ohtake S, Miyazaki Y, Ohnishi K, Kobayashi Y, Naoe T: Tamibarotene as maintenance therapy for acute promyelocytic leukemia: results from a randomized controlled trial. J Clin Oncol, 32(33): 3729-3735, 2014.
Tachibana T, Tanaka M, Numata A, Matsumoto K, Tomita N, Fujimaki K, Taguchi J, Sakai R, Fujita H, Fujisawa S, Maruta A, Ishigatsubo Y, Kanamori H: Clinical significance of pre- and 1 year post- transplant serum ferritin among adult transplant recipients. Leuk Lymphoma, 55(6): 1350-1356, 2014.
Tachibana T, Tanaka M, Yamazaki E, Numata A, Takasaki H, Kuwabara H, Fujimaki K, Sakai R, Fujita H, Fujisawa S, Maruta A, Ishigatsubo Y, Kanamori H: Multicenter validation of scoring system of pre-transplant serum ferritin and disease risk in patients with acute myeloid leukemia and myelodysplastic syndrome after allogeneic hematopoietic stem cell transplant. Leuk Lymphoma, 54(6): 1318-1320, 2014.
Takami A, Yano S, Yokoyama H, Kuwatsuka Y, Yamaguchi T, Kanda Y, Morishima Y, Fukuda T, Miyazaki Y, Nakamae H, Tanaka J, Atsuta Y, Kanamori H: Donor lymphocyte infusion for the treatment of relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation: A retrospective analysis by the Adult AML Working Group of the Japan Society for Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant, 20(11): 1785-1790, 2014.
Watanabe R, Tomita N, Itabashi M, Ishibashi D, Yamamoto E, Koyama S, Miyashita K, Takahashi H, Nakajima Y, Hattori Y, Motohashi K, Takasaki H, Ohshima R, Hashimoto C, Yamazaki E, Fujimaki K, Sakai R, Fujisawa S, Motomura S, Ishigatsubo Y: Peripheral blood absolute lymphocyte/monocyte ratio as a useful prognostic factor in diffuse large B-cell lymphoma in the rituximab era. Eur J Haematol, 92(3): 204-210, 2014.
Yamamoto E, Fujisawa S, Hagihara M, Tanaka M, Fujimaki K, Kishimoto K, Hashimoto C, Itabashi M, Ishibashi D, Nakajima Y, Tachibana T, Kawasaki R, Kuwabara H, Koharazawa H, Yamazaki E, Tomita N, Sakai R, Fujita H, Kanamori H, Ishigatsubo Y: European Treatment and Outcome Study score does not predict imatinib treatment response and outcome in chronic myeloid leukemia patients. Cancer Sci, 105(1): 105-109, 2014.
Yamamoto W, Ogusa E, Matsumoto K, Maruta A, Ishigatsubo Y, Kanamori H: Human herpesvirus-6 encephalopathy after hematopoietic stem cell transplantation and class I human leukocyte antigen. Clin Transplant, 28(5): 540-545, 2014.
Yamamoto W, Ogusa E, Matsumoto K, Maruta A, Ishigatsubo Y, Kanamori H: Lymphocyte recovery on day 100 after allogeneic hematopoietic stem cell transplantation predicts non-relapse mortality in patients with acute leukemia or myelodysplastic syndrome. Leuk Lymphoma, 55(5): 1113-1118, 2014.
Yamamoto W, Ogusa E, Matsumoto K, Maruta A, Ishigatsubo Y, Kanamori H: Predictive value of risk assessment scores in patients with hematologic malignancies undergoing reduced-intensity conditioning allogeneic stem cell transplantation. Am J Hematol, 89(9): E138-141, 2014.
Yamamoto W, Nakamura N, Tomita N, Takeuchi K, Ishii Y, Takahashi H, Watanabe R, Takasaki H, Motomura S, Kobayashi S, Yokose T, Ishigatsubo Y, Sakai R: HLA-DR expression on flow cytometry and tumor-associated macrophages in diffuse large B cell lymphoma treated by R-CHOP therapy: Retrospective cohort study. Leuk Lymphoma, 55(12): 2721-2727, 2014.
Yamazaki E, Tomita N, Koyama S, Ogusa E, Ishii Y, Takahashi H, Miyashita K, Matsuura S,Tachibana T, Takasaki H, Takemura S, Fujimaki K, Sakai R, Fujisawa S, Ishigatsubo Y: Serum ferritin level is prognostic of patient outcome in extranoda NK/T cell lymphoma, nasal type. Med Oncol, 31(9):149, 2014.
Yamamoto W, Takasaki H, Isii Y, Fujita A, Hashimoto C, Takemura S, Motomura S, Tomita N, Ishigatsubo Y, Sakai R: Modified anthracycline-based chemotherapy for elderly patients with diffuse large B-cell lymphoma in the rituximab era. 横浜医学, 65: 1-6, 2014.
